Lü Peng-Hua, Zhang Xi-Cheng, Wang Li-Fu, Shi Hai-Bin
Department of Radiology, First Hospital Affiliated to Nanjing Medical University, Nanjing, China Department of Interventional Radiology, Northern Jiangsu People's Hospital, Yangzhou, China.
Department of Vascular Surgery, Northern Jiangsu People's Hospital, Yangzhou, China.
Vasc Endovascular Surg. 2014 Jul-Aug;48(5-6):406-11. doi: 10.1177/1538574414543275.
Spontaneous isolated superior mesenteric artery dissection (ISMAD) is exceedingly rare. The therapeutic options range from observation to medical treatment to surgery or endovascular repair. We present our experience of the clinical management of ISMADs.
Sixteen patients with ISMAD from January 2008 to July 2012 were retrospectively analyzed. The decision to intervene was based on anatomic suitability, patient comorbidities, and symptoms. Percutaneous endovascular reconstruction with bare stents was carried out in 7 patients in this study, for patients with persistent abdominal pain despite conservative treatment or signs of bowel ischemia. The patients were kept on antiplatelet therapy from 6 to 10 months postoperatively.
All attempted bare stent placements were successfully accomplished without any treatment-related complication. Of the 7 patients with ISMADs, 4 were treated by single stents, 2 by double overlapping stents, and 1 by triple overlapping stents. The abdominal pain alleviated after procedure and disappeared gradually within 3 days. None of the patients had ISMAD symptoms during follow-up (median, 21.7 months; range, 11-32 months). Follow-up computed tomography (CT) and CT angiography revealed patent stent and patent superior mesenteric artery (SMA) branches with complete obliteration of the dissection.
Isolated SMA dissection may be managed successfully in a variety of ways based on the clinical symptoms. In this small series, percutaneous endovascular reconstruction with bare stent implantation is a feasible treatment choice with a high success rate and good clinical outcome.
自发性孤立性肠系膜上动脉夹层(ISMAD)极为罕见。治疗选择范围从观察、药物治疗到手术或血管腔内修复。我们介绍我们对ISMAD临床管理的经验。
回顾性分析2008年1月至2012年7月期间的16例ISMAD患者。干预决策基于解剖学适宜性、患者合并症和症状。本研究中7例患者接受了裸支架经皮血管腔内重建,这些患者尽管接受了保守治疗仍有持续性腹痛或有肠缺血迹象。患者术后接受6至10个月的抗血小板治疗。
所有尝试的裸支架置入均成功完成,无任何与治疗相关的并发症。在7例ISMAD患者中,4例采用单支架治疗,2例采用双重叠支架治疗,1例采用三重叠支架治疗。术后腹痛缓解,并在3天内逐渐消失。随访期间(中位时间21.7个月;范围11 - 32个月),所有患者均无ISMAD症状。随访计算机断层扫描(CT)和CT血管造影显示支架通畅,肠系膜上动脉(SMA)分支通畅,夹层完全闭塞。
根据临床症状,孤立性SMA夹层可以通过多种方式成功处理。在这个小系列研究中,裸支架植入的经皮血管腔内重建是一种可行的治疗选择,成功率高,临床效果良好。